Skip to main content
Top
Published in: Archives of Public Health 1/2018

Open Access 01-12-2018 | Study protocol

Longitudinal pharmacoepidemiological and health services research for substance users in treatment: protocol of the Belgian TDI-IMA linkage

Authors: Luk Van Baelen, Karin De Ridder, Jérôme Antoine, Lies Gremeaux

Published in: Archives of Public Health | Issue 1/2018

Login to get access

Abstract

Background

Not much is known about the health seeking behavior of people with substance use disorders before they enter specialized treatment and afterwards. This paper explains in detail the protocol that has been followed to establish the Belgian TDI-IMA-database, which is linking two separate databases: the Treatment Demand Indicator (TDI) and the database of the Intermutualistic Agency (IMA). The Treatment Demand Indicator is measuring incidence of people with substance use disorders entering drug treatment. The IMA-database covers data, collected in the framework of the compulsory Belgian health care and benefits insurance program, on reimbursed medication and the use of reimbursed health services. The linkage results in pharmacoepidemiological and health service data for people who were in treatment for substance use disorders and for a group of comparators.

Methods

The TDI-database was linked to the IMA-database for the period between 01/01/2008 and 31/12/2017, based on the national identification number of patients who have been in alcohol or drug treatment between 01/01/2011 and 31/12/2014. Through this linkage, pharmacoepidemiological and health service data became available for at least 3 years before the first registered episode in the TDI-database till at least 3 years after the first episode. For each person in TDI four comparators, who were not in specialized treatment, were matched on age, sex and place of residence.

Discussion

The TDI-IMA-database allows for an analysis of health seeking behavior and health care pathways of people before and after they entered specialized alcohol and drug treatment. The presented protocol could be used in other European countries to establish a linkage between existing health databases. This will allow for a better understanding of the health care needs of patients with substance use disorders.
Literature
1.
go back to reference Furu K, Br W, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for Pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106:86–94.CrossRefPubMed Furu K, Br W, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for Pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106:86–94.CrossRefPubMed
2.
go back to reference Kildemoes H, Sørensen H, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39:38–41.CrossRefPubMed Kildemoes H, Sørensen H, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39:38–41.CrossRefPubMed
3.
go back to reference Torstensson M, Hansen AH, Leth-Møller K, Jørgensen TSH, Sahlberg M, Andersson C, Kristensen KE, Ryg J, Weeke P, Torp-Pedersen C, et al. Danish register-based study on the association between specific cardiovascular drugs and fragility fractures. BMJ Open. 2015;5:e009522.CrossRefPubMedPubMedCentral Torstensson M, Hansen AH, Leth-Møller K, Jørgensen TSH, Sahlberg M, Andersson C, Kristensen KE, Ryg J, Weeke P, Torp-Pedersen C, et al. Danish register-based study on the association between specific cardiovascular drugs and fragility fractures. BMJ Open. 2015;5:e009522.CrossRefPubMedPubMedCentral
4.
5.
go back to reference Pigeot I, Ahrens W. Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf. 2008;17:215–23.CrossRefPubMed Pigeot I, Ahrens W. Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf. 2008;17:215–23.CrossRefPubMed
6.
go back to reference Støvring H. The use of Pharmacoepidemiological databases to assess disease burdens: application to diabetes. In: Preedy VR, Watson RR, editors. Handbook of disease burdens and quality of life measures. New York, NY: Springer New York; 2010. p. 671–84.CrossRef Støvring H. The use of Pharmacoepidemiological databases to assess disease burdens: application to diabetes. In: Preedy VR, Watson RR, editors. Handbook of disease burdens and quality of life measures. New York, NY: Springer New York; 2010. p. 671–84.CrossRef
7.
go back to reference Prins MA, Verhaak PF, Smit D, Verheij RA. Healthcare utilization in general practice before and after psychological treatment: a follow-up data linkage study in primary care. Scand J Prim Health Care. 2014;32:117–23.CrossRefPubMedPubMedCentral Prins MA, Verhaak PF, Smit D, Verheij RA. Healthcare utilization in general practice before and after psychological treatment: a follow-up data linkage study in primary care. Scand J Prim Health Care. 2014;32:117–23.CrossRefPubMedPubMedCentral
8.
go back to reference Hemmelgarn B, Blais L, Collet J, Ernst P, Suissa S. Automated databases and the need for fieldwork in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 1994;3:275–82.CrossRef Hemmelgarn B, Blais L, Collet J, Ernst P, Suissa S. Automated databases and the need for fieldwork in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 1994;3:275–82.CrossRef
9.
go back to reference Evans E, Grella CE, Murphy DA, Hser YI. Using administrative data for longitudinal substance abuse research. J Behav Health Serv Res. 2010;37:252–71.CrossRefPubMed Evans E, Grella CE, Murphy DA, Hser YI. Using administrative data for longitudinal substance abuse research. J Behav Health Serv Res. 2010;37:252–71.CrossRefPubMed
10.
go back to reference Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009;104:1193–200.CrossRefPubMed Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009;104:1193–200.CrossRefPubMed
11.
go back to reference Antoine J, De Ridder K, Plettinckx E, Blanckaert P, Gremeaux L. Treatment for substance use disorders: the Belgian treatment demand indicator registration protocol. Archives Public Health. 2016;74:27.CrossRef Antoine J, De Ridder K, Plettinckx E, Blanckaert P, Gremeaux L. Treatment for substance use disorders: the Belgian treatment demand indicator registration protocol. Archives Public Health. 2016;74:27.CrossRef
12.
go back to reference Conférence interministérielle Santé publique: Enregistrement des demandes de traitement via le Treatment Demand Indicator. 2006/22273, 22932–22934. 3–5-2006. Conférence interministérielle Santé publique: Enregistrement des demandes de traitement via le Treatment Demand Indicator. 2006/22273, 22932–22934. 3–5-2006.
13.
go back to reference Commissie voor de bescherming van de persoonlijke levenssfeer: Beraadslaging nr. 15/033 van 19 mei 2015 met betrekking tot de mededeling van gecodeerde persoonsgegevens betreffende de gezondheid door het IMA en het TDI-register aan het Wetenschappelijk Instituut Volksgezondheid in het kader van een wetenschappelijke studie (SCSZG/15/078). 2015. Commissie voor de bescherming van de persoonlijke levenssfeer: Beraadslaging nr. 15/033 van 19 mei 2015 met betrekking tot de mededeling van gecodeerde persoonsgegevens betreffende de gezondheid door het IMA en het TDI-register aan het Wetenschappelijk Instituut Volksgezondheid in het kader van een wetenschappelijke studie (SCSZG/15/078). 2015.
15.
go back to reference Grimes DA, Schulz KF. Compared to what? Finding comparators for case-control studies. Lancet. 2016;365:1429–33.CrossRef Grimes DA, Schulz KF. Compared to what? Finding comparators for case-control studies. Lancet. 2016;365:1429–33.CrossRef
16.
go back to reference Antoine J, De TDI-registratie in België. Jaarlijks rapport, registratiejaar 2015. Scientific Institute of Public Health. Brussels. 2016; Antoine J, De TDI-registratie in België. Jaarlijks rapport, registratiejaar 2015. Scientific Institute of Public Health. Brussels. 2016;
17.
go back to reference Conférence interministérielle Santé publique: Protocole d'accord des ministres qui ont la santé publique dans leurs compétences concernant l'enregistrement des demandes de traitement en matière de drogues et d'alcool via l'opérationnalisation du Treatment Demand Indicator européen. 30–9-2013. Conférence interministérielle Santé publique: Protocole d'accord des ministres qui ont la santé publique dans leurs compétences concernant l'enregistrement des demandes de traitement en matière de drogues et d'alcool via l'opérationnalisation du Treatment Demand Indicator européen. 30–9-2013.
20.
go back to reference Br W, Hammar N, Fored C, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundström A, Westerholm B, Rosén M. The new Swedish prescribed drug register - οpportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidem Drug Safe. 2007;16:726–35.CrossRef Br W, Hammar N, Fored C, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundström A, Westerholm B, Rosén M. The new Swedish prescribed drug register - οpportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidem Drug Safe. 2007;16:726–35.CrossRef
21.
go back to reference Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2007;379:55–70.CrossRef Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2007;379:55–70.CrossRef
22.
go back to reference Forouzanfar M, Afshin A, Alexander L, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1659–724.CrossRef Forouzanfar M, Afshin A, Alexander L, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1659–724.CrossRef
23.
go back to reference Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, Freedman G, Burstein R, Johns N, Engell RE, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the global burden of disease study 2010. Lancet. 2013;382:1564–74.CrossRefPubMed Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, Freedman G, Burstein R, Johns N, Engell RE, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the global burden of disease study 2010. Lancet. 2013;382:1564–74.CrossRefPubMed
24.
go back to reference Hovstadius B, Petersson G. Non-adherence to drug therapy and drug acquisition costs in a national population - a patient-based register study. BMC Health Service Research. 2011;11:326.CrossRef Hovstadius B, Petersson G. Non-adherence to drug therapy and drug acquisition costs in a national population - a patient-based register study. BMC Health Service Research. 2011;11:326.CrossRef
25.
go back to reference Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15.CrossRefPubMedPubMedCentral Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15.CrossRefPubMedPubMedCentral
26.
27.
go back to reference World Health Organization (WHO). Adherence to long-term therapies: evidence for action. 2003. World Health Organization (WHO). Adherence to long-term therapies: evidence for action. 2003.
28.
go back to reference Kapil V, Green JL, Le Lait MC, Wood DM, Dargan PI. Misuse of the ϒ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 2014;78:190–1.CrossRefPubMed Kapil V, Green JL, Le Lait MC, Wood DM, Dargan PI. Misuse of the ϒ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 2014;78:190–1.CrossRefPubMed
29.
go back to reference Schifano F, D’Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, Di Melchiorre G, Di Furia L, Farré M, Flesland L, et al. Is there a recreational misuse potential for Pregabalin? Analysis of anecdotal online reports in comparison with related Gabapentin and Clonazepam data. Psychother Psychosom. 2011;80:118–22.CrossRefPubMed Schifano F, D’Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, Di Melchiorre G, Di Furia L, Farré M, Flesland L, et al. Is there a recreational misuse potential for Pregabalin? Analysis of anecdotal online reports in comparison with related Gabapentin and Clonazepam data. Psychother Psychosom. 2011;80:118–22.CrossRefPubMed
Metadata
Title
Longitudinal pharmacoepidemiological and health services research for substance users in treatment: protocol of the Belgian TDI-IMA linkage
Authors
Luk Van Baelen
Karin De Ridder
Jérôme Antoine
Lies Gremeaux
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Archives of Public Health / Issue 1/2018
Electronic ISSN: 2049-3258
DOI
https://doi.org/10.1186/s13690-017-0249-x

Other articles of this Issue 1/2018

Archives of Public Health 1/2018 Go to the issue